|Combination antiretroviral therapy and the risk of myocardial infarction|
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
|Decline in the AIDS and death rates in the EuroSIDA study: an observational study|
A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, AA Monforte, ...
The Lancet 362 (9377), 22-29, 2003
|Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study|
S Collins, T Mertenskoetter, E Loeliger, R Tressler, I Weller, N Friis-M°ller, ...
Archives of internal medicine 166 (15), 1632-1641, 2006
|Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration|
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
|Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients|
AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ...
Aids 14 (5), 499-507, 2000
|Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort|
D Konopnicki, A Mocroft, S De Wit, F Antunes, B Ledergerber, C Katlama, ...
Aids 19 (6), 593-601, 2005
|AIDS across Europe, 1994–98: the EuroSIDA study|
A Mocroft, C Katlama, AM Johnson, C Pradier, F Antunes, F Mulcahy, ...
The Lancet 356 (9226), 291-296, 2000
|Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration|
CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, ...
The Lancet 384 (9939), 241-248, 2014
|Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients|
A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, ...
Aids 24 (11), 1667-1678, 2010
|Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study|
A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, ...
Aids 16 (12), 1663-1671, 2002
|Influence of age on CD4 cell recovery in human immunodeficiency virus–infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study|
JP Viard, A Mocroft, A Chiesi, O Kirk, B R°ge, G Panos, N Vetter, ...
The Journal of infectious diseases 183 (8), 1290-1294, 2001
|Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.|
LJD m L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA ...
J Infect Dis 207 (9), 1359-69, 2013
|Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya|
L Ryom, A Mocroft, O Kirk, SW Worm, DA Kamara, P Reiss, M Ross, ...
The Journal of infectious diseases 207 (9), 1359-1369, 2013
|Serious fatal and nonfatal non-AIDS-defining illnesses in Europe|
A Mocroft, P Reiss, J Gasiorowski, B Ledergerber, J Kowalska, A Chiesi, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (2), 262-270, 2010
|Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America|
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
|One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects|
M Airoldi, M Zaccarelli, L Bisi, T Bini, A Antinori, C Mussini, F Bai, ...
Patient preference and adherence 4, 115, 2010
|Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study|
JP Viard, JC Souberbielle, O Kirk, J Reekie, B Knysz, M Losso, J Gatell, ...
Aids 25 (10), 1305-1315, 2011
|Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users|
M DAVOLI, CA PERUCCI, F FORASTIERE, PAT DOYLE, E RAPITI, ...
International Journal of Epidemiology 22 (2), 273-277, 1993
|A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival|
A Mocroft, S Madge, AM Johnson, A Lazzarin, N Clumeck, FD Goebel, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 22 (4), 369-378, 1999
|Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure|
A Antinori, M Zaccarelli, A Cingolani, F Forbici, MG Rizzo, MP Trotta, ...
AIDS research and human retroviruses 18 (12), 835-838, 2002